eprintid: 510 rev_number: 7 eprint_status: archive userid: 2 dir: disk0/00/00/05/10 datestamp: 2022-02-08 23:55:05 lastmod: 2023-06-30 23:30:20 status_changed: 2022-02-08 23:55:05 type: article metadata_visibility: show creators_name: Marcos Rodríguez, Ana Teresa creators_name: Navarro-Pando, José Manuel creators_id: anateresa.marcos@uneatlantico.es creators_id: jose.navarro@uneatlantico.es title: Letter: cfDNA testing in recurrent pregnancy loss: a new step in the right way but still raw for the clinical area ispublished: pub subjects: uneat_bm divisions: uneatlantico_produccion_cientifica full_text_status: none abstract: Sir, In their recently published study, Yaron et al. (2020) expose an interesting strategy based in cfDNA testing (cfDNA-T) which could serve as an alternative to cytogenetic analysis in products of conceptions in recurrent pregnancy loss and could guide further management of this medical topic; however, in our opinion, some important aspects should be considered. Firstly, Illanes et al. (2007) found that cfDNA concentration in the maternal blood can be detected from Week 4 of gestation but it is only reliable from Week 7. However, others authors’ experience could be different. Clark-Ganheart et al. (2015) recommend cfDNA analysis only after 8 weeks of gestation. Zeevi et al. (2018) reported that aneuploidy screening by cfDNA is not generally accurate before Week 8, leading to a period in pregnancy (namely, Weeks 4 through 8) during which assessment of the genetic status of the embryo is not generally feasible. Galeva et al.... date: 2020-12 date_type: published publication: Human Reproduction volume: 36 number: 3 pagerange: 827-829 id_number: doi:10.1093/humrep/deaa359 refereed: TRUE issn: 0268-1161 official_url: http://doi.org/10.1093/humrep/deaa359 access: close language: en citation: Artículo Materias > Biomedicina Universidad Europea del Atlántico > Investigación > Producción Científica Cerrado Inglés Sir, In their recently published study, Yaron et al. (2020) expose an interesting strategy based in cfDNA testing (cfDNA-T) which could serve as an alternative to cytogenetic analysis in products of conceptions in recurrent pregnancy loss and could guide further management of this medical topic; however, in our opinion, some important aspects should be considered. Firstly, Illanes et al. (2007) found that cfDNA concentration in the maternal blood can be detected from Week 4 of gestation but it is only reliable from Week 7. However, others authors’ experience could be different. Clark-Ganheart et al. (2015) recommend cfDNA analysis only after 8 weeks of gestation. Zeevi et al. (2018) reported that aneuploidy screening by cfDNA is not generally accurate before Week 8, leading to a period in pregnancy (namely, Weeks 4 through 8) during which assessment of the genetic status of the embryo is not generally feasible. Galeva et al.... metadata Marcos Rodríguez, Ana Teresa y Navarro-Pando, José Manuel mail anateresa.marcos@uneatlantico.es, jose.navarro@uneatlantico.es (2020) Letter: cfDNA testing in recurrent pregnancy loss: a new step in the right way but still raw for the clinical area. Human Reproduction, 36 (3). pp. 827-829. ISSN 0268-1161